Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Andrew B. Nixon, Jamie N. Bakkum‐Gamez et al.|Clinical Cancer Research|2020Cited by 57
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Andrew B. Nixon, Jing Lyu et al.|Molecular Cancer Therapeutics|2020Cited by 30
Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).Andrew B. Nixon, Herbert I. Hurwitz, Alexander B. Sibley et al.|Journal of Clinical Oncology|2016Cited by 15
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K. Choueiri, Neeraj Agarwal, Yousef Zakharia et al.|The Oncologist|2021Cited by 10
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.Yingmiao Liu, Andrew B. Nixon, Zhenhua Yuan et al.|Journal of Clinical Oncology|2017Cited by 1